- Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy - CAMBRIDGE, Mass., January 23, 2012-Millennium: The Takeda Oncology Company with ...

ORLANDO, Fla.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous ...

SC administration of VELCADE also demonstrated acceptable local tolerability. Only 6 percent of patients had at least one SC local injection site reaction reported as an adverse event, with the most ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company, Takeda Pharmaceutical Company Limited (TSE:4502), today announced that the U.S. Food and Drug ...

May 19, 2003 — Editor's Note: On May 12, the U.S. Food and Drug Administration (FDA) approved Velcade (bortezomib), the first drug in its class of proteasome inhibitors, for the treatment of patients ...

Millennium Pharmaceuticals reported results from two Phase 3 studies of Velcade (bortezomib injection); the first study compared Velcade and rituximab to rituximab monotherapy for the treatment of ...

-- Data on use of VELCADE in follicular lymphoma to be featured in additional oral presentation -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company today announced abstracts ...

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Bortezomib for Injection in the United States. The product contains ...

Kyprolis doubled progression-free survival versus Velcade in patients with relapsed multiple myeloma in the phase 3 ENDEAVOR trial. Kyprolis (carfilzomib) doubled progression-free survival (PFS) ...

The Food and Drug Administration yesterday approved Millennium Pharmaceuticals ' cancer drug Velcade to treat multiple myeloma, a deadly blood cancer. The FDA approved Velcade in a record four months.

This morning, Millennium Pharmaceuticals said it had asked the U.S. Food and Drug Administration to approve its first cancer drug, Velcade, as a treatment for multiple myeloma, a cancer of the blood ...

- Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy - CAMBRIDGE, Mass., January 23, 2012-Millennium: The Takeda Oncology Company with ...